Narrow search
Showing 1 - 10 of 610,550
Cover Image
Impact of parallel trade on pharmaceutical firm’s profits : rise or fall?
Hu, Bin - 2019
Most existing studies on parallel trade conclude that it reduces pharmaceutical firms' profits. One special feature of the pharmaceutical industry is the presence of price regulation in most countries. Taking into account the impact of parallel trade on the regulated pharmaceutical prices shows...
Persistent link: https://www.econbiz.de/10012871310
Cover Image
Implementing personalized medicine with asymmetric information on prevalence rates
Antoñanzas Villar, Fernando; Juárez-Castelló, Carmelo A. - In: Health economics review 6 (2016) 35, pp. 1-8
Although personalized medicine is becoming the new paradigm to manage some diseases, the economics of personalized medicine have only focused on assessing the efficiency of specific treatments, lacking a theoretical framework analyzing the interactions between pharmaceutical firms and healthcare...
Persistent link: https://www.econbiz.de/10011586604
Cover Image
Pharmaceutical regulation at the wholesale level and parallel trade
Birg, Laura - 2013
This paper studies the effect of pharmaceutical regulation at the wholesale level, if markets are integrated by parallel trade, i.e. trade outside the manufacturerś authorized distribution channel. In particular, maximum wholesale margins, a restriction of pricing by the intermediary, and...
Persistent link: https://www.econbiz.de/10010223101
Cover Image
Externalities of National Pharmaceutical Policy when Markets are Integrated through Parallel Trade
Birg, Laura - 2017
This paper studies externalities of nationally determined cost-sharing systems, in particular coinsurance rates (patients pay a percentage of the price), under pharmaceutical parallel trade in a two-country model with a vertical distributor relationship. Parallel trade generates a...
Persistent link: https://www.econbiz.de/10012973688
Cover Image
Price caps versus reimbursement limits : pharmaceutical regulation under market integration through parallel trade
Birg, Laura - 2019 - Revised Version March 2019
In this paper, I study the effect of parallel trade (cross border resale of goods without the authorization of the manufacturer) on pharmaceutical regulation in a North-South framework with a firm's endogenous decision to export to the South. Governments in both countries may limit prices...
Persistent link: https://www.econbiz.de/10011986314
Cover Image
Estimating the Cost of Strategic Entry Delay in Pharmaceuticals : The Case of Ambien CR
Shapiro, Bradley - 2016
With the Hatch-Waxman Act of 1984, the FDA included an unchallengeable exclusivity period for newly approved drugs, independent of patents. This potentially generates an incentive for firms to strategically delay the introduction of new versions (reformulations) of drugs until just before patent...
Persistent link: https://www.econbiz.de/10014135034
Cover Image
Science, Scarcity and Public Health : The Search for New Pharma Models
Abbott, Frederick M. - 2015
These are neither the best of times nor the worst of times for the pharmaceutical industry, or for global public health. Media reports regarding recent legal developments would suggest that the originator pharmaceutical industry is facing a new and dangerous threat to its long-term welfare,...
Persistent link: https://www.econbiz.de/10014141859
Cover Image
Regulating Ambiguous Risks : The Less than Rational Regulation of Pharmaceuticals
Viscusi, W. Kip; Zeckhauser, Richard J. - 2015
The U.S. Food and Drug Administration (FDA) balances risks and benefits before approving pharmaceuticals, as …
Persistent link: https://www.econbiz.de/10014148944
Cover Image
Parallel Trade in Pharmaceuticals : Trade Therapy for Market Distortions
Abbott, Frederick M. - 2017
, particularly from an economic standpoint. In this regard, pharmaceuticals are not generally traded in what might be described as a … because it is imported. Parallel trade (i.e., imports and exports) in pharmaceuticals takes place in markets that are … international exhaustion. This should help to facilitate price reductions in the global market for pharmaceuticals …
Persistent link: https://www.econbiz.de/10014124812
Cover Image
Optimal Patent Policy for Pharmaceutical Industry
Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2020
We show how characterizing optimal patent policy for the pharmaceutical industry only requires information about generic producers' responses to changes in the effective duration and scope of new drug patents. To estimate these responses, we use data on Paragraph IV patent challenges, and two...
Persistent link: https://www.econbiz.de/10014097057